You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmobarbital
Accession NumberDB01351
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
Structure
Thumb
Synonyms
5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-(3-methylbutyl)barbituric acid
5-Ethyl-5-isoamylbarbituric acid
5-Ethyl-5-isopentylbarbituric acid
Amobarbital
Amylobarbitone
Amytal
Barbamil
Barbamyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amytal Sodium 500mgPowder, for solution500 mgIntramuscular; IntravenousEli Lilly Canada Inc1939-12-312003-07-30Canada
Amytal Sodium Cap 60mgCapsule60 mgOralPharmascience Inc1951-12-312004-03-05Canada
Amytal Sodium Pulvule 222 0.2gmCapsule200 mgOralPharmascience Inc1939-12-312004-03-05Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amytal SodiumInjection, powder, lyophilized, for solution.5 g/5mLIntramuscular; IntravenousValeant Pharmaceuticals North America LLC2008-09-25Not applicableUs
Amytal SodiumInjection, powder, lyophilized, for solution.5 g/5mLIntramuscular; IntravenousMarathon Pharmaceuticals, LLC2008-09-252016-10-13Us
International Brands
NameCompany
IsomytalNot Available
Brand mixtures
NameLabellerIngredients
Tuinal Pulvule 303Pharmascience Inc
Tuinal Pulvule 304Pharmascience Inc
Salts
Name/CASStructureProperties
Amobarbital sodium
ThumbNot applicableDBSALT001490
Categories
UNIIGWH6IJ239E
CAS number57-43-2
WeightAverage: 226.2722
Monoisotopic: 226.131742452
Chemical FormulaC11H18N2O3
InChI KeyVIROVYVQCGLCII-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
SMILES
CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionAmobarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Amobarbital also appears to bind neuronal nicotinic acetylcholine receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Amobarbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with 7-Nitroindazole.Experimental
AcebutololAmobarbital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Amobarbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Amobarbital.Approved
AcetazolamideAmobarbital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Amobarbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Agomelatine.Approved, Investigational
AldesleukinAmobarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amobarbital.Approved, Illicit
AliskirenAmobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Amobarbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Amobarbital.Experimental
AmifostineAmobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Amobarbital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Amobarbital.Approved
AmiodaroneAmobarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Amobarbital.Approved
AmlodipineAmobarbital may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amperozide.Experimental
Amphotericin BAmobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Amobarbital.Approved
Amyl NitriteAmobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Amobarbital.Investigational
ApomorphineAmobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineAmobarbital may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Amobarbital.Approved
Arsenic trioxideAmobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Asenapine.Approved
AtenololAmobarbital may increase the hypotensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Azaperone.Vet Approved
AzelastineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Amobarbital.Approved
Azilsartan medoxomilAmobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Amobarbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Amobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Amobarbital.Experimental
BenazeprilAmobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideAmobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Amobarbital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amobarbital.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amobarbital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Amobarbital.Approved, Withdrawn
BetaxololAmobarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.Approved
BisoprololAmobarbital may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Amobarbital.Approved
BortezomibAmobarbital may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumAmobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam.Approved, Illicit
BromocriptineAmobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Amobarbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Amobarbital.Experimental, Investigational
BumetanideAmobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amobarbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.Approved
BuprenorphineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amobarbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amobarbital.Approved, Illicit, Vet Approved
CaiThe metabolism of Cai can be increased when combined with Amobarbital.Investigational
CanagliflozinAmobarbital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanAmobarbital may increase the hypotensive activities of Candesartan.Approved
CaptoprilAmobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amobarbital.Approved, Investigational
CarbetocinAmobarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carisoprodol.Approved
CarteololAmobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolAmobarbital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Amobarbital.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Amobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amobarbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amobarbital.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amobarbital.Approved
ChlorothiazideAmobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Amobarbital.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amobarbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amobarbital.Approved, Withdrawn
ChlorthalidoneAmobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorzoxazone.Approved
CilazaprilAmobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Amobarbital.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amobarbital.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Amobarbital.Approved
CitalopramThe risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clemastine.Approved
ClevidipineAmobarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clobazam.Approved, Illicit
ClofarabineAmobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Amobarbital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amobarbital.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amobarbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amobarbital.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amobarbital.Approved, Illicit
ConivaptanAmobarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Amobarbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Amobarbital.Approved
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Amobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.Approved
DapagliflozinAmobarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amobarbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Amobarbital.Experimental
deramciclaneThe risk or severity of adverse effects can be increased when Amobarbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Amobarbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Amobarbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amobarbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amobarbital.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amobarbital.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amobarbital.Approved, Illicit, Vet Approved
DiclofenamideAmobarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Amobarbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Amobarbital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Amobarbital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Amobarbital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemAmobarbital may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dimenhydrinate.Approved
DinutuximabAmobarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amobarbital.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amobarbital.Approved, Illicit
DipyridamoleAmobarbital may increase the hypotensive activities of Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Amobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Amobarbital.Investigational
DoxazosinAmobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Amobarbital.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Amobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Amobarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Amobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Amobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Amobarbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Amobarbital.Approved
EmpagliflozinAmobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilAmobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAmobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amobarbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Entacapone.Approved, Investigational
EperisoneThe metabolism of Eperisone can be increased when combined with Amobarbital.Approved, Investigational
EplerenoneAmobarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolAmobarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAmobarbital may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Amobarbital.Investigational
EsmololAmobarbital may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amobarbital.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Amobarbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Amobarbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Amobarbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Amobarbital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amobarbital.Approved
Etacrynic acidAmobarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amobarbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Amobarbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Amobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Amobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amobarbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Amobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Amobarbital can be increased when it is combined with Felbamate.Approved
FelodipineAmobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Amobarbital.Withdrawn
FenoldopamAmobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amobarbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fexofenadine.Approved
FimasartanAmobarbital may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Amobarbital.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amobarbital.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amobarbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amobarbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amobarbital.Approved, Investigational
FosinoprilAmobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fospropofol.Approved, Illicit
FurosemideAmobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amobarbital.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amobarbital is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Amobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Amobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Amobarbital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Amobarbital.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amobarbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amobarbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Amobarbital.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Hexobarbital.Approved
HydralazineAmobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAmobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideAmobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Iloperidone.Approved
IloprostAmobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilAmobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Amobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideAmobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Amobarbital.Withdrawn
IndoraminAmobarbital may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanAmobarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidAmobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amobarbital.Approved, Vet Approved
Isosorbide DinitrateAmobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateAmobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineAmobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineAmobarbital may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amobarbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketobemidone.Approved
LabetalolAmobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Amobarbital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Amobarbital.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Amobarbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levetiracetam.Approved, Investigational
LevobunololAmobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amobarbital.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amobarbital.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Amobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amobarbital.Approved
LevosimendanAmobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amobarbital.Approved, Vet Approved
LisinoprilAmobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lofentanil.Illicit
LofexidineAmobarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amobarbital.Approved
LosartanAmobarbital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amobarbital.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Amobarbital is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Amobarbital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Amobarbital.Approved
MannitolAmobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Maprotiline.Approved
MecamylamineAmobarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Amobarbital.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amobarbital.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amobarbital.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amobarbital.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Amobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Amobarbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideAmobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amobarbital.Approved
MethotrimeprazineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amobarbital.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methsuximide.Approved
MethyclothiazideAmobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaAmobarbital may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.Approved
MetipranololAmobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneAmobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololAmobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineAmobarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Amobarbital.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Amobarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Investigational
MinoxidilAmobarbital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilAmobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amobarbital.Approved, Investigational
MoxonidineAmobarbital may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Investigational
NadololAmobarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Amobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amobarbital.Approved
NebivololAmobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nefazodone.Approved, Withdrawn
NesiritideAmobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineAmobarbital may increase the hypotensive activities of Nicardipine.Approved
NifedipineAmobarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Amobarbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Amobarbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Amobarbital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Amobarbital.Approved, Withdrawn
NimodipineAmobarbital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineAmobarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Amobarbital.Approved
Nitric OxideAmobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinAmobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideAmobarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Amobarbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Amobarbital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Amobarbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Amobarbital.Approved
ObinutuzumabAmobarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amobarbital.Approved, Investigational
OlmesartanAmobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amobarbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Amobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Amobarbital is combined with Opium.Approved, Illicit
OrphenadrineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amobarbital.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Amobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amobarbital.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amobarbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amobarbital.Approved, Investigational, Vet Approved
PaclitaxelAmobarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amobarbital.Approved
PapaverineAmobarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.Approved, Investigational
PenbutololAmobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Amobarbital.Approved
PerindoprilAmobarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amobarbital.Approved
PethidineAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineAmobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Amobarbital.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.Approved
PhenoxybenzamineAmobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Amobarbital.Approved
PhentolamineAmobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amobarbital.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Amobarbital.Approved
PindololAmobarbital may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pizotifen.Approved
PolythiazideAmobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Amobarbital.Approved
PramipexoleAmobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam.Approved, Illicit
PrazosinAmobarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amobarbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Amobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amobarbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Amobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amobarbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Amobarbital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amobarbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Propoxycaine.Approved
PropranololAmobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Amobarbital.Approved
PSD502The risk or severity of adverse effects can be increased when Amobarbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Amobarbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.Approved
QuinaprilAmobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneAmobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ramelteon.Approved, Investigational
RamiprilAmobarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineAmobarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amobarbital.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amobarbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amobarbital.Approved
RifabutinThe metabolism of Amobarbital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Amobarbital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Amobarbital can be increased when combined with Rifapentine.Approved
RiociguatAmobarbital may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Amobarbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Romifidine.Vet Approved
RopiniroleAmobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital.Approved
RotigotineAmobarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amobarbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Amobarbital is combined with S-Ethylisothiourea.Experimental
SacubitrilAmobarbital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Amobarbital is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amobarbital.Approved, Vet Approved
SelegilineAmobarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amobarbital.Approved, Vet Approved
Sodium NitriteAmobarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Amobarbital.Approved
SotalolAmobarbital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneAmobarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Stiripentol.Approved
StreptokinaseAmobarbital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amobarbital.Approved
SuvorexantAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Amobarbital.Approved
TamsulosinAmobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tasimelteon.Approved
TelmisartanAmobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Amobarbital.Approved
TerazosinAmobarbital may increase the hypotensive activities of Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrodotoxin.Investigational
ThalidomideAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Amobarbital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amobarbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amobarbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amobarbital.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Amobarbital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiletamine.Vet Approved
TimololAmobarbital may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tizanidine.Approved
TolazolineAmobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Amobarbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Amobarbital is combined with Topiramate.Approved
TorasemideAmobarbital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amobarbital.Approved, Investigational
TrandolaprilAmobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Amobarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amobarbital.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Amobarbital.Approved, Investigational
TretinoinAmobarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneAmobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amobarbital.Approved
TrichlormethiazideAmobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Amobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Amobarbital is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Amobarbital.Approved
Valproic AcidThe serum concentration of Amobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanAmobarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Venlafaxine.Approved
VerapamilAmobarbital may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Amobarbital.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Amobarbital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Amobarbital.Approved
XylazineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Amobarbital.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amobarbital.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zolazepam.Vet Approved
ZolpidemAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amobarbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kim HS, Wan X, Mathers DA, Puil E: Selective GABA-receptor actions of amobarbital on thalamic neurons. Br J Pharmacol. 2004 Oct;143(4):485-94. Epub 2004 Sep 20. [PubMed:15381635 ]
  2. Maynert EW: The alcoholic metabolites of pentobarbital and amobarbital in man. J Pharmacol Exp Ther. 1965 Oct;150(1):118-21. [PubMed:5855308 ]
  3. Tang BK, Kalow W, Grey AA: Amobarbital metabolism in man: N-glucoside formation. Res Commun Chem Pathol Pharmacol. 1978 Jul;21(1):45-53. [PubMed:684279 ]
  4. Soine PJ, Soine WH: High-performance liquid chromatographic determination of the diastereomers of 1-(beta-D-glucopyranosyl)amobarbital in urine. J Chromatogr. 1987 Nov 27;422:309-14. [PubMed:3437019 ]
  5. McCall WV: The addition of intravenous caffeine during an amobarbital interview. J Psychiatry Neurosci. 1992 Nov;17(5):195-7. [PubMed:1489761 ]
External Links
ATC CodesN05CA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9254
Blood Brain Barrier+0.949
Caco-2 permeable-0.5913
P-glycoprotein substrateSubstrate0.6471
P-glycoprotein inhibitor INon-inhibitor0.5906
P-glycoprotein inhibitor IINon-inhibitor0.9426
Renal organic cation transporterNon-inhibitor0.9307
CYP450 2C9 substrateNon-substrate0.7591
CYP450 2D6 substrateNon-substrate0.9011
CYP450 3A4 substrateNon-substrate0.663
CYP450 1A2 substrateNon-inhibitor0.879
CYP450 2C9 inhibitorNon-inhibitor0.7603
CYP450 2D6 inhibitorNon-inhibitor0.9299
CYP450 2C19 inhibitorNon-inhibitor0.7269
CYP450 3A4 inhibitorNon-inhibitor0.9422
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9105
Ames testNon AMES toxic0.691
CarcinogenicityNon-carcinogens0.8925
BiodegradationNot ready biodegradable0.944
Rat acute toxicity2.9884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.8963
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous.5 g/5mL
Powder, for solutionIntramuscular; Intravenous500 mg
CapsuleOral60 mg
CapsuleOral200 mg
CapsuleOral
Prices
Unit descriptionCostUnit
Amytal sodium 0.5 gram vial117.35USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157 °CPhysProp
water solubility603 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.07HANSCH,C ET AL. (1995)
logS-2.57ADME Research, USCD
pKa7.84SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.897 mg/mLALOGPS
logP1.87ALOGPS
logP1.89ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58 m3·mol-1ChemAxon
Polarizability23.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.4 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-4900000000-8b443325c415e154ac85View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  4. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:48 / Updated on August 17, 2016 12:23